Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension.

Research output: Contribution to journalArticle

Standard

Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension. / Patel, Jeetesh; Lim, Hoong; Rohalu, Kiran; Hughes, Elizabeth; Lip, Gregory.

In: Annals of Medicine, 26.01.2009, p. 1-10.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{9fdcb977ca3543d5b9ec9b5bd0fb1910,
title = "Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension.",
abstract = "Background. Abnormal adipocyte function is implicated in the coalition of multiple cardiovascular risk factors, where aberrant circulating levels of the adipose-derived hormones adiponectin, leptin, and tumour necrosis factor (TNF) alpha may provide the putative link between hypertension and increased cardiovascular risk. The pragmatic utility of these 'adipocytokines' in the clinical setting of hypertension is unclear, and we hypothesized a relationship of circulating adipocytokines to hypertension, and associated cardiovascular morbidity. Method. Using a cross-sectional approach, we measured plasma adipocytokines in 278 'high-risk' treated hypertensive participants of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) study (mean (SD) age 62.9 (7.7) years), who were compared to 54 newly diagnosed untreated hypertensives (61.3 (10.9) years) and 55 healthy controls (48.3 (12.3) years). Results. Levels of all three adipocytokines were lower amongst treated hypertensives compared to newly diagnosed hypertensives and healthy controls (P",
author = "Jeetesh Patel and Hoong Lim and Kiran Rohalu and Elizabeth Hughes and Gregory Lip",
year = "2009",
month = jan,
day = "26",
doi = "10.1080/07853890802672839",
language = "English",
pages = "1--10",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Taylor & Francis",

}

RIS

TY - JOUR

T1 - Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension.

AU - Patel, Jeetesh

AU - Lim, Hoong

AU - Rohalu, Kiran

AU - Hughes, Elizabeth

AU - Lip, Gregory

PY - 2009/1/26

Y1 - 2009/1/26

N2 - Background. Abnormal adipocyte function is implicated in the coalition of multiple cardiovascular risk factors, where aberrant circulating levels of the adipose-derived hormones adiponectin, leptin, and tumour necrosis factor (TNF) alpha may provide the putative link between hypertension and increased cardiovascular risk. The pragmatic utility of these 'adipocytokines' in the clinical setting of hypertension is unclear, and we hypothesized a relationship of circulating adipocytokines to hypertension, and associated cardiovascular morbidity. Method. Using a cross-sectional approach, we measured plasma adipocytokines in 278 'high-risk' treated hypertensive participants of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) study (mean (SD) age 62.9 (7.7) years), who were compared to 54 newly diagnosed untreated hypertensives (61.3 (10.9) years) and 55 healthy controls (48.3 (12.3) years). Results. Levels of all three adipocytokines were lower amongst treated hypertensives compared to newly diagnosed hypertensives and healthy controls (P

AB - Background. Abnormal adipocyte function is implicated in the coalition of multiple cardiovascular risk factors, where aberrant circulating levels of the adipose-derived hormones adiponectin, leptin, and tumour necrosis factor (TNF) alpha may provide the putative link between hypertension and increased cardiovascular risk. The pragmatic utility of these 'adipocytokines' in the clinical setting of hypertension is unclear, and we hypothesized a relationship of circulating adipocytokines to hypertension, and associated cardiovascular morbidity. Method. Using a cross-sectional approach, we measured plasma adipocytokines in 278 'high-risk' treated hypertensive participants of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) study (mean (SD) age 62.9 (7.7) years), who were compared to 54 newly diagnosed untreated hypertensives (61.3 (10.9) years) and 55 healthy controls (48.3 (12.3) years). Results. Levels of all three adipocytokines were lower amongst treated hypertensives compared to newly diagnosed hypertensives and healthy controls (P

U2 - 10.1080/07853890802672839

DO - 10.1080/07853890802672839

M3 - Article

C2 - 19172446

SP - 1

EP - 10

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

ER -